Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus nab-paclitaxel and carboplatin for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2300070894Phase 4Completed
- Sponsor
- Yangzhong People's Hospital
- Start
- Dec 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Yangzhong People's Hospital. Primary endpoint: pathological complete response. Started Dec 2021; status: completed.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300070894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070894.